Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment
Jing-wen Guo, Guo‐Qiang Lin, Xinyi Tang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access | Times Cited: 2
Recent Progress in the Development of Glucose Transporter (GLUT) Inhibitors
Yuxuan Wang, Zhiqiang Sun, Zean Zhao, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability
Xiaoyu Shi, Tong Zhao, Shuo Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 5032-5052
Closed Access | Times Cited: 8
Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents
Zhiqiang Sun, Xuewen Zhang, Zean Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 19966-19987
Closed Access | Times Cited: 7
Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia
Fengxin Zheng, Suiqing Mai, Xiaolin Cen, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107381-107381
Closed Access | Times Cited: 6
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout
Zihan Hou, Aijinxiu Ma, Jiale Mao, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 895-909
Closed Access | Times Cited: 16
Targeting purine metabolism-related enzymes for therapeutic intervention: A review from molecular mechanism to therapeutic breakthrough
Di Wu, Shengqiang Yang, Chenyang Yuan, et al.
International Journal of Biological Macromolecules (2024), pp. 136828-136828
Closed Access | Times Cited: 4
Loss of Urat1 exacerbates APAP-induced liver injury in mice
Kunlu Zhao, Shuaishuai Zhang, Jinhong Tian, et al.
Toxicology (2025), pp. 154070-154070
Closed Access
A promising strategy for assessing the uricosuric effect of anti-hyperuricemia candidates: a case study of caffeoylquinic acids extract of Artemisia selengensis Turcz. leaves
Xiang Lin, Mohammed Mansour, Yuting Huang, et al.
Food, Nutrition and Health. (2025) Vol. 2, Iss. 1
Open Access
Genomic Inference Unveils Population Bottlenecks and a North-to-South Migration Pattern of Wild Cordyceps militaris Across China
Tianqiao Yong, Yuanchao Liu, Manjun Cai, et al.
Agriculture (2025) Vol. 15, Iss. 7, pp. 686-686
Open Access
Research Progress on the Biological Activity of Isobavachin
文渊 张
Journal of Organic Chemistry Research (2025) Vol. 13, Iss. 01, pp. 70-76
Closed Access
Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout
Xinye Yang, Yong Li, Shengqiang Pan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14668-14691
Closed Access | Times Cited: 2
Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents
Zean Zhao, Xinhua Chen, Jiajun Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116753-116753
Closed Access | Times Cited: 2
Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production
Yongjun Chen, Zitao Guo, Hai-Qiao Chen, et al.
Chemico-Biological Interactions (2024) Vol. 403, pp. 111220-111220
Closed Access | Times Cited: 2
Pathology, target discovery, and the evolution of XO inhibitors from the first discovery to recent advances (2020–2023)
Nitish Kumar, Komalpreet Kaur, Navjot Kaur, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 107042-107042
Closed Access | Times Cited: 6
Natural Bioactive Compounds: Emerging Therapies for Hyperuricemia
Yafei Liu, Kaifeng Zheng, Huanhuan Wang, et al.
The American Journal of Chinese Medicine (2024), pp. 1-23
Closed Access | Times Cited: 1
Isobavachin attenuates FcεRI-mediated inflammatory allergic responses by regulating SHP-1-dependent Fyn/Lyn/Syk/Lck signaling
Kenice Siew Hoon Sim, Eunkyung Lee, Prafulla Shrestha, et al.
Biochemical Pharmacology (2024) Vol. 232, pp. 116698-116698
Closed Access | Times Cited: 1
Discovery and Characterization of Moracin C as an Anti-Gouty Arthritis/Hyperuricemia Candidate by Docking-Based Virtual Screening and Pharmacological Evaluation
Min‐Yi Lv, Shaoyan Jiang, Shaojie Deng, et al.
Journal of Natural Products (2023) Vol. 86, Iss. 9, pp. 2091-2101
Closed Access | Times Cited: 3
Development and Validation of a Novel Fluorescence-Based Hk-2 Cell Model for Assessing Uricosuric Effects: Application to Artemisia Selengensis Turcz. Leaves
Xiang Lin, Mohammed Mansour, Yuting Huang, et al.
(2024)
Closed Access
Effect of Xanthohumol from Humulus lupulus L. Against Gouty Bone Damage in Arthritis of Rats Induced by Mono-sodium Urate
Jianyong Han, Tianshuang Xia, Yiping Jiang, et al.
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 4, pp. 3425-3435
Closed Access
The development of a novel high-throughput membrane potential assay and a solid-supported membrane (SSM)-based electrophysiological assay to study the pharmacological inhibition of GLUT9/SLC2A9 isoforms in a drug discovery program
Antje Pommereau, Francesca Sassone, Alessandro Poli, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 8, pp. 100193-100193
Open Access
Page 1

Scroll to top